Cargando…
Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
PURPOSE: Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597414/ https://www.ncbi.nlm.nih.gov/pubmed/31281726 http://dx.doi.org/10.4048/jbc.2019.22.e29 |
_version_ | 1783430578555584512 |
---|---|
author | Yu, Dehai Shi, Libo Bu, Yuhui Li, Weidong |
author_facet | Yu, Dehai Shi, Libo Bu, Yuhui Li, Weidong |
author_sort | Yu, Dehai |
collection | PubMed |
description | PURPOSE: Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary and metastatic ER-positive BC patients. Although tamoxifen is currently one of the most successful therapeutic agents for BC, a significant proportion of patients will eventually become resistant to tamoxifen, leading to tumor recurrence and metastasis. Knowledge about the development of tamoxifen resistance in BC patients is still limited. METHODS: We applied a loss-and-gain method to study the biological functional role of cell division cycle associated 8 (CDCA8) in tamoxifen resistance in BC cells. RESULTS: We found that CDCA8 was significantly elevated in tamoxifen-resistant BC cells. Knockdown of CDCA8 expression significantly inhibited the proliferation of tamoxifen-resistant BC cells and reduced their resistance to tamoxifen. In contrast, overexpression of CDCA8 promoted the growth of tamoxifen-sensitive BC cells and induced their resistance to tamoxifen. CONCLUSION: In this study, we reported that CDCA8 is a key regulator of tamoxifen resistance in BC, suggesting that CDCA8 may serve as a potential therapeutic target for BC treatment. |
format | Online Article Text |
id | pubmed-6597414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Breast Cancer Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65974142019-07-05 Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer Yu, Dehai Shi, Libo Bu, Yuhui Li, Weidong J Breast Cancer Original Article PURPOSE: Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary and metastatic ER-positive BC patients. Although tamoxifen is currently one of the most successful therapeutic agents for BC, a significant proportion of patients will eventually become resistant to tamoxifen, leading to tumor recurrence and metastasis. Knowledge about the development of tamoxifen resistance in BC patients is still limited. METHODS: We applied a loss-and-gain method to study the biological functional role of cell division cycle associated 8 (CDCA8) in tamoxifen resistance in BC cells. RESULTS: We found that CDCA8 was significantly elevated in tamoxifen-resistant BC cells. Knockdown of CDCA8 expression significantly inhibited the proliferation of tamoxifen-resistant BC cells and reduced their resistance to tamoxifen. In contrast, overexpression of CDCA8 promoted the growth of tamoxifen-sensitive BC cells and induced their resistance to tamoxifen. CONCLUSION: In this study, we reported that CDCA8 is a key regulator of tamoxifen resistance in BC, suggesting that CDCA8 may serve as a potential therapeutic target for BC treatment. Korean Breast Cancer Society 2019-06-07 /pmc/articles/PMC6597414/ /pubmed/31281726 http://dx.doi.org/10.4048/jbc.2019.22.e29 Text en © 2019 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yu, Dehai Shi, Libo Bu, Yuhui Li, Weidong Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer |
title | Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer |
title_full | Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer |
title_fullStr | Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer |
title_full_unstemmed | Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer |
title_short | Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer |
title_sort | cell division cycle associated 8 is a key regulator of tamoxifen resistance in breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597414/ https://www.ncbi.nlm.nih.gov/pubmed/31281726 http://dx.doi.org/10.4048/jbc.2019.22.e29 |
work_keys_str_mv | AT yudehai celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer AT shilibo celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer AT buyuhui celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer AT liweidong celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer |